Journal · Hematologic cancers · Updated 22 November 2026
Current Hematologic Malignancy Reports
Read Current Hematologic Malignancy Reports articles on DeepDyve. No university library needed.
Current Hematologic Malignancy Reports has published since 2006 and publishes reviews on leukemia, lymphoma, myeloma and other blood cancers, with recent papers on drug resistance in chronic lymphocytic and chronic myeloid leukemia, residual disease testing in myeloma, BRAF alterations and immunotherapy escape in B-cell leukemia. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.
Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.
Personal plans aren’t for business use. Reading for work? See Enterprise.
Current Hematologic Malignancy Reports at a glance
- Full title
- Current Hematologic Malignancy Reports
- Abbreviation (NLM)
- Curr Hematol Malig Rep
- Publisher
- Springer Nature
- Print ISSN
- 1558-8211
- Online ISSN (eISSN)
- 1558-822X
- First published
- 2006
- Subjects
- Hematology, Neoplasms
- Access model
- Hybrid (52% free to read in 2026)
Ways to access Current Hematologic Malignancy Reports
52% of the articles Current Hematologic Malignancy Reports published from January 1 to November 20, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.
- Open access articles. 52% of Current Hematologic Malignancy Reports articles published from January 1 to November 20, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
- The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
- Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
- NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
- A library. Your university, hospital or public library may subscribe to Current Hematologic Malignancy Reports. Check its journal list and whether it offers remote access.
- DeepDyve. Read Current Hematologic Malignancy Reports articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.
Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.
Impact factor and metrics
Current Hematologic Malignancy Reports’ 2025 Journal Impact Factor is 4.0, and its 5-year Impact Factor is 2.9.
4.0
Journal Impact Factor (2025)
2.9
5-year Impact Factor (2025)
3 days
Median time to first decision
Source: journal metrics on the Current Hematologic Malignancy Reports homepage (Springer Nature), checked November 22, 2026. Impact Factor from Clarivate Journal Citation Reports.
Recent Current Hematologic Malignancy Reports research worth reading
Published February to August 2026. Summaries describe what the authors report.
-
When Targeted Therapy Falls Short: Unraveling Resistance Mechanisms in Chronic Lymphocytic Leukemia
The authors review how chronic lymphocytic leukemia resists targeted drugs, through mutations that block BTK inhibitor binding or remove BTK kinase activity and through Bcl-2 mutations and AKT-driven escape from venetoclax, and note work on next-generation inhibitors and protein degraders.
Benrashid et al. · Current Hematologic Malignancy Reports, published online February 26, 2026 · DOI 10.1007/s11899-026-00776-3
-
New Approaches for Measurable Residual Disease Assessment in Multiple Myeloma: Integrating NGS, Mass Spectrometry, and Next-Generation Flow Cytometry to Monitor Treatment Response
The authors review measurable residual disease testing in multiple myeloma, where bone marrow flow cytometry and sequencing remain the standard, and describe blood-based mass spectrometry assays and newer tools such as cell-free DNA sequencing that could make monitoring less invasive.
Mohan Lal et al. · Current Hematologic Malignancy Reports, published online February 14, 2026 · DOI 10.1007/s11899-026-00771-8
-
BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance
Reviewing BRAF alterations in chronic lymphocytic leukemia, the authors report they appear in about 2–6% of unselected cohorts, recur at relapse after targeted therapy and are best seen as part of MAPK signaling rather than as a standalone biomarker or drug target.
Al-Abdulmalek et al. · Current Hematologic Malignancy Reports, published online May 1, 2026 · DOI 10.1007/s11899-026-00780-7
-
Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia
The authors review resistance to tyrosine kinase inhibitors in chronic myeloid leukemia, from BCR::ABL1 mutations to added abnormalities such as ASXL1 and RUNX1, and describe early promising activity of newer agents and of asciminib combined with ATP-site inhibitors.
Naderi et al. · Current Hematologic Malignancy Reports, published online April 25, 2026 · DOI 10.1007/s11899-026-00778-1
-
Antigen Pressure, Clonal Evolution, and Lineage Plasticity in B-Cell Acute Lymphoblastic Leukemia: Resistance Biology in the Immunotherapy Era
The authors review how B-cell acute lymphoblastic leukemia escapes antigen-directed immunotherapy, distinguishing antigen loss, linked more to TP53 mutations, from lineage switch, enriched in KMT2A-rearranged disease and carrying a median overall survival of about 4.8 months.
Thiebaud et al. · Current Hematologic Malignancy Reports, published online August 7, 2026 · DOI 10.1007/s11899-026-00784-3
See every Current Hematologic Malignancy Reports article on DeepDyve
Related journals
Questions about Current Hematologic Malignancy Reports
How can I read Current Hematologic Malignancy Reports articles without a subscription?
52% of Current Hematologic Malignancy Reports articles published from January 1 to November 20, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Current Hematologic Malignancy Reports articles online for $59 a month or $499 a year after a free first month.
What is the abbreviation for Current Hematologic Malignancy Reports?
Current Hematologic Malignancy Reports’ NLM (PubMed) abbreviation is Curr Hematol Malig Rep.
What is the ISSN of Current Hematologic Malignancy Reports?
The print ISSN is 1558-8211 and the online ISSN is 1558-822X.
What is the impact factor of Current Hematologic Malignancy Reports?
Current Hematologic Malignancy Reports’ Journal Impact Factor is 4.0 (2025), and its 5-year Impact Factor is 2.9, according to Springer Nature’s published metrics.
Is Current Hematologic Malignancy Reports open access?
Current Hematologic Malignancy Reports is a hybrid journal: authors can choose to publish open access or under the subscription model. From January 1 to November 20, 2026, 13 of 25 Current Hematologic Malignancy Reports articles (52%) carry a Creative Commons license, per Crossref.
Current Hematologic Malignancy Reports articles on DeepDyve are licensed from Springer Nature. Journal facts as of 22 November 2026.
Start reading Current Hematologic Malignancy Reports today
One month free, then less than $2 a day. Current Hematologic Malignancy Reports, plus millions of articles from thousands of journals.





